IPP Bureau
Avandra Health acquires DatCard and Sorna to build industry-leading medical imaging platform
By IPP Bureau - December 03, 2025
The acquisitions merge DatCard and Sorna’s expertise in clinical data sharing with Avandra’s de-identified patient data aggregation platform
Imugene reports strong early results for Azer-cel in aggressive blood cancer trial
By IPP Bureau - December 03, 2025
Celltrion gets Health Canada nod for Eylea biosimilar Eydenzelt
By IPP Bureau - December 03, 2025
Health Canada’s approval was based on a comprehensive evaluation of analytical, nonclinical, and clinical data
EIB, Angelini Ventures team up to pump €150 million into European biotech, digital health startups
By IPP Bureau - December 03, 2025
Angelini Ventures has already invested €125 million in 22 startups
L&T Technology unveils next-gen AI digital twin for lung diagnostics
By IPP Bureau - December 03, 2025
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
Citius Oncology's new therapy offers new hope for cutaneous T-cell lymphoma patients
By IPP Bureau - December 03, 2025
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
Merck unveils first human data for Alzheimer’s candidates
By IPP Bureau - December 03, 2025
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Sound's for hearing loss: Co's drug wins FDA breakthrough tag for Meniere’s disease
By IPP Bureau - December 03, 2025
Here's a new ray of hope for new hope for patients suffering from Meniere’s disease (MD) and sensorineural hearing loss
Biocon Biologics secures market entry date for Denosumab biosimilars in Europe, Rest of the World
By IPP Bureau - December 03, 2025
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
US District Court grants summary judgement in Favour of SPARC for Sezaby PRV
By IPP Bureau - December 03, 2025
FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved'
US & UK reach historic pharma pricing pact
By IPP Bureau - December 03, 2025
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
AbbVie’s Atogepant shows breakthrough results for acute migraine relief
By IPP Bureau - December 03, 2025
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Belite Bio reports landmark phase 3 success for Stargardt Disease therapy
By IPP Bureau - December 03, 2025
Seeing well-controlled Phase 3 data that shows a marked slowing of lesion growth in Stargardt disease is deeply encouraging
LENZ Therapeutics, Lotus Pharmaceutical submit NDA for presbyopia treatment in Korea
By IPP Bureau - December 03, 2025
Presbyopia, the age-related loss of near vision, could soon be treated successfully
WHO urges rapid expansion of new HIV prevention tools amid funding crisis
By IPP Bureau - December 03, 2025
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
